Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future ...

This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...

Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort study suggested that a low baseline PSA level in midlife was associated with a ...

High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer. Real-world characteristics of long-term survivors with metastatic castration-resistant prostate ...

Credit: Getty Images Findings have implications for counseling patients treated with radiation therapy plus ADT in routine clinical practice. PSA levels of 0.1 ng/mL or higher within 6 months of ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

Kindly let me know if it is possible to have a normal PSA level and still develop Prostate Cancer. Dagogo (by SMS) Although this is possible, it is highly unlikely. The PSA is a test for the antigen ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...